Eye Drug Study Blindsided Pharma Co. Investors, Suit Says

By Emilie Ruscoe · January 2, 2025, 9:26 PM EST

The CEO and directors of biopharmaceutical company Apellis Pharmaceuticals Inc. face shareholder derivative claims they failed to monitor clinical study participants for a serious side effect, leading to plummeting trading prices...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Complaint

Case Information

Case Title

Olson v. Francois et al

Case Number

Court

Massachusetts

Nature of Suit

Securities/Commodities

Date Filed

December 30, 2024

Recent Articles By Emilie

December 16, 2024
Ginkgo Bioworks Investors Get Final OK Of $17.8M Settlement
December 13, 2024
Pharma Co. Brass Face Investor Suit Over Drug Trial Probe
December 06, 2024
Two Firms To Rep CVS Investors In Benefit Unit Losses Suit
November 05, 2024
Bright Health Beats Investor Suit Over COVID-19 Costs
October 30, 2024
LA Times Owner Faces Investor Suit Over Drug Co.'s Woes
October 28, 2024
Moderna Brass Hit With Investor Suit Over RSV Shot Claims
October 22, 2024
Pharma Co. Verrica Faces Derivative Suit Over FDA Inspection
October 16, 2024
Pharma Co. Contractor Settles SEC Insider Trading Claim
September 24, 2024
Biotech RenovaCare Investors Seek OK Of $2M Deal
September 03, 2024
Teva Investors Get Go-Ahead To Resume Kickbacks Class Suit